Merck & Co. Inc.is cancelling development of a Zocor-based combination of its cholesterol product Tredaptive, but the firm is still moving forward with the statin-free combination of niacin and the novel anti-flushing compound laropiprant.
MK-0524B was a combination of the investigational drug Tredaptive (niacin/laropiprant), aka MK-0524A, and Merck’s blockbuster simvastatin, which went off patent...